-
South America, Asia, and Europe.
BioMarin's core
business and
research is in
enzyme replacement therapies (ERTs).
BioMarin was the
first company to provide...
- 2023,
Elliott Investment Management spent over $1
billion on a
stake in
BioMarin,
which focuses on rare
genetic disorders and is
valued at
about $16 billion...
-
produced in 2000,
followed by
testing in
animal models until 2014. In 2012,
BioMarin began the
first clinical trial on
affected patients using their recombinant...
- salt form,
which was
developed through a
series of
companies ending with
BioMarin Pharmaceutical which obtained European approval in 2009
under the brand...
- is a
synthetic version of this enzyme.
Elosulfase alfa was
developed by
BioMarin Pharmaceutical Inc. and
approved for use in the US by the Food and Drug...
- gene
therapy used for the
treatment of
hemophilia A. It was
developed by
BioMarin Pharmaceutical.
Valoctocogene roxaparvovec is made of a
virus (AAV5) that...
- on 2020-08-05. "
BioMarin : Pipeline:
Pipeline Overview: BMN 165 for PKU". bmrn.com.
Archived from the
original on 2015-01-01. "
BioMarin Provides Updates...
- from the
index on July 24 due to its
acquisition by AT&T and
replaced by
BioMarin Pharmaceutical on July 27. Sigma-Aldrich was
removed on July 31, after...
-
Approves BioMarin's Voxzogo (vosoritide) for the
Treatment of
Children with
Achondroplasia from Age 2
Until Growth Plates Close" (Press release).
BioMarin Pharmaceutical...
-
typical cost of
treating a
patient with
Kuvan is US$100,000 per year.
BioMarin holds the
patent for
Kuvan until at
least 2024, but Par Pharmaceutical...
